Newsroom | 5778 results
Sorted by: Latest
-
WM Technology, Inc. Reports Second Quarter 2026 Financial Results
IRVINE, Calif.--(BUSINESS WIRE)--WM Technology, Inc. (“WM Technology” or the “Company”) (OTC: MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced its financial results for the second quarter ended June 30, 2026. “The cannabis industry is entering a more demanding phase, particularly in established markets where sustained economic and regulatory pressures continue to reshape the competitive landscape,” said Doug Francis, CEO and Chairman of WM...
-
Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, and will participate in a fireside chat at 8:00am ET. Management will also participate in the Stifel Biotech Summit in Newport, Rhode Island, on August 10, 2026. A live audio webcast of this event wil...
-
Cresco Labs Reports Second Quarter 2026 Financial Results; Delivers $173 Million in Revenue and $40 Million in Adjusted EBITDA
CHICAGO--(BUSINESS WIRE)--Cresco Labs Reports Second Quarter 2026 Financial Results; Delivers $173 Million in Revenue and $40 Million in Adjusted EBITDA...
-
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the second quarter and first half 2026 financial results and business highlights. “The first half of 2026 marked a defining period for Compass as we continued to build momentum across clinical, regulatory and commercial fronts in preparation for the potential approval and launch of COMP360,” said Kabir...
-
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a webcast at 4:30 p.m. EDT on Thursday, August 6, 2026 to report financial results for the second quarter ended June 30, 2026, and discuss recent business highlights. Listeners can register for the webcast via this link....
-
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics. “The final guidance reflects the FDA’s continued engagement with clinical developme...
-
Canopy Growth to Report First Quarter Fiscal 2027 Financial Results on August 7, 2026
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth to report Q1 2027 financial results on August 7 with a conference call at 10:00am ET....
-
New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
LEVERKUSEN, Germany--(BUSINESS WIRE)--Self-care, when effectively integrated into health systems, can improve health outcomes, expand access to healthcare services and reduce pressure on overstretched health systems, according to new research by Economist Enterprise. The research, supported by Bayer and published in a report titled “Making self-care work: integrating self-care into health systems”, cites existing evidence estimating that self-care practices can deliver approximately US$ 179 bil...
-
NMS Labs Announces Promotion of Gregory Schuh as Chief Financial Officer
HORSHAM, Pa.--(BUSINESS WIRE)--NMS Labs, a national leader in forensic and clinical toxicology services, is pleased to announce the promotion of Gregory Schuh to Chief Financial Officer, effective July 21, 2026. His promotion reflects NMS Labs’ continued investment in operational excellence, financial stewardship, and commercial growth. Greg joined NMS Labs in April 2023 as Controller. In this role, he oversaw the organization’s finance and accounting functions, supporting both day-to-day opera...
-
N-Zyme Biomedical Closes US$4.6 Million Series A Financing to Advance Clinical Development
NEWARK, Del. & WAUWATOSA, Wis.--(BUSINESS WIRE)--N-Zyme Biomedical Closes US$4.6 Million Series A Financing to Advance Clinical Development....